Larimar Therapeutics, Inc.
US ˙ NasdaqGM ˙ US5171251003

SecurityLRMR / Larimar Therapeutics, Inc.
InstitutionQUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series
Latest Disclosed Ownership70,068 shares
Latest Disclosed Value $ 202,496
QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series ownership in LRMR / Larimar Therapeutics, Inc.

On August 26, 2025 - QUANTITATIVE MASTER SERIES LLC - Master Small Cap Index Series filed a NPORT-P form disclosing ownership of 70,068 shares of Larimar Therapeutics, Inc. (US:LRMR) valued at $202,497 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 28, 2025 disclosing 70,068 shares of Larimar Therapeutics, Inc.. This represents a change in shares of 0.00% during the quarter. The current value of the position is $222,116 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-26 2025-06-30 NP Larimar Therapeutics EC US5171251003 70,068 0 0.00 202 34.67 0.0045
2025-05-28 2025-03-31 NP Larimar Therapeutics EC US5171251003 70,068 0 0.00 151 -44.65 0.0036
2025-02-25 2024-12-31 NP Larimar Therapeutics EC US5171251003 70,068 -13,811 -16.47 271 -50.64 0.0059
2024-11-26 2024-09-30 NP Larimar Therapeutics EC US5171251003 83,879 33,889 67.79 549 51.66 0.0104
2024-08-26 2024-06-30 NP Larimar Therapeutics EC US5171251003 49,990 0 0.00 362 -4.49 0.0074
2024-05-28 2024-03-31 NP Larimar Therapeutics EC US5171251003 49,990 0 0.00 379 66.96 0.0079
2024-02-26 2023-12-31 NP Larimar Therapeutics EC US5171251003 49,990 9,200 22.55 227 40.99 0.0049
2023-11-28 2023-09-30 NP Larimar Therapeutics EC US5171251003 40,790 0 0.00 161 26.77 0.0042
2023-08-25 2023-06-30 NP Larimar Therapeutics EC US5171251003 40,790 40,790 128 0.0030
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.